Doxazosin Effects on ABPM in Hypertensive Patients With Diabetic Nephropathy
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Few studies have reported the effect of alpha1-adrenergic antagonists on 24-h blood pressure and regulation of sympathetic nervous activity in hypertensive patients with diabetic nephropathy. Using ambulatory blood pressure monitoring devices equipped with spectral analysis of heart rate variability, we assess the effects of doxazosin on blood pressure in diabetic nephropathy patients and compare the results with those in patients with essential hypertension, patients with diabetes mellitus and patients with chronic nephropathy.
| Condition | Intervention | Phase |
|---|---|---|
|
Diabetes Mellitus Essential Hypertension Renal Failure |
Drug: Effects of doxazosin on morning surge in diabetic patients |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy |
- Normalization of high blood pressure [ Time Frame: One year ]
| Enrollment: | 98 |
| Study Start Date: | January 2004 |
| Study Completion Date: | April 2007 |
The study is an open-labeled parallel prospective trial comparing the effects of doxazosin (2-8 mg/day) on 24-h blood pressure and autonomic nervous activity. Hypertensive patients with non-insulin-dependent diabetic nephropathy, patients with essential hypertension, patients with diabetes mellitus and patients with chronic nephropathy undergo ambulatory blood pressure monitoring before and after treatment with doxazosin. Simultaneously, spectral analysis is performed to calculate the high frequency components as a marker of parasympathetic nervous activity, and the low frequency components/high frequency components ratios as an index of the sympathovagal balance.
Eligibility| Ages Eligible for Study: | 20 Years to 79 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Hypertensive patients with diabetes mellitus
- Hypertensive patients
- Hypertensive patients with renal disease
Exclusion Criteria:
- Cardiac, hematologic or hepatic disease
- Renal insufficiency (serum creatinine values> 2 mg/L)
- Hormone-induced hypertension
- Cerebral infarction or hemorrhage
- Other major diseases
Contacts and Locations| Japan | |
| Yokohama City University Center Hospital | |
| Yokohama, Japan, 232-0024 | |
| Principal Investigator: | Gen Yasuda, MD | Yokohama City University Center Hospital |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00295555 History of Changes |
| Other Study ID Numbers: | 7332-2 |
| Study First Received: | February 21, 2006 |
| Last Updated: | May 8, 2007 |
| Health Authority: | Japan: Ministry of Health, Labor and Welfare |
Keywords provided by Yokohama City University Medical Center:
|
ambulatory blood pressure monitoring doxazosin alpha1-adrenergic antagonists sympathetic nervous activity |
diabetic nephropathy essential hypertension power spectral analysis morning surge |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetic Nephropathies Hypertension Kidney Diseases Renal Insufficiency Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Urologic Diseases Diabetes Complications Vascular Diseases Cardiovascular Diseases |
Doxazosin Adrenergic Antagonists Antihypertensive Agents Cardiovascular Agents Therapeutic Uses Pharmacologic Actions Adrenergic alpha-1 Receptor Antagonists Adrenergic alpha-Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on June 17, 2013